REGENXBIO reported a third-quarter net loss of $40.7 million, down from $61.9 million a year earlier. Revenue fell to $9.2 million from $29.7 million, mainly because US patents on Zolgensma royalties expired in January 2026. The company booked a $38.0 million gain from a patent settlement with Sarepta Therapeutics, which paid $39.0 million in October. Cash and securities stood at $251.0 million on September 30, helped by a $100.0 million milestone payment from AbbVie and $107.8 million in net proceeds from a public offering. REGENXBIO says cash, plus the Sarepta payment, should fund operations into late Q4 2027. Topline pivotal data for sura-vec in wet AMD, developed with AbbVie, is due this quarter. The company plans to submit a Biologics License Application for its Duchenne therapy, RGX-202, in Q1 2027.

REGENXBIO to participate in Stifel 2026 Healthcare Conference. Nov 03, 2026, 07:05 ET ROCKVILLE, Md., Nov. 3, 2026 /PRNewswire/ - REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Stifel 2026 Healthcare Conference. Fireside Chat Details Date and Time: Wednesday, November 11, 2026 at 9:20 a.m. ET Location: New York, NY A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcasts will be available for approximately 30 days following the event. ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA(R) and ITVISMA(R). REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM. Investors: George E. MacDougall Investor Relations [email protected] SOURCE REGENXBIO Inc.

REGENXBIO schedules October 20 event: REGENXBIO stock gains 8.87 percent. Published on 10/20/2026 at 19:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Sura-vec event was set for October 20, 2026. REGENXBIO stock costs EUR 6.70 on October 20, 2026, up 8.87 percent versus Tradegate close. Reporting date October 20, 2026. * REGENXBIO scheduled its Sura-vec investor event for October 20, 2026. * Second-quarter 2026 revenue reached USD 108.02 million, USD 10.39 million above consensus. * REGENXBIO stock costs EUR 6.70 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST, 8.87 percent above the Tradegate close of October 16, 2026. * The next quarterly update is listed for November 5, 2026. REGENXBIO (US75901B1070) had scheduled its Sura-vec investor event for October 20, 2026, highlighting surabgene lomparvovec in wet age-related macular degeneration, according to REGENXBIO. The stock was trading at EUR 6.70 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST, up 8.87 percent versus the Tradegate close of October 16, 2026 at EUR 6.15. Revenue beat adds financial support. The company's second-quarter 2026 revenue reached USD 108.02 million, compared with consensus of USD 97.63 million, a difference of USD 10.39 million. MarketBeat reported that adjusted earnings per share were USD 0.43, above the USD 0.08 consensus estimate, for the quarter ended June 30, 2026. Stock stays below the yearly high. At EUR 6.70, the Lang & Schwarz price stood 53.79 percent below the 52-week high of EUR 14.50 and 40.70 percent above the 52-week low of EUR 4.76. The primary Nasdaq listing last traded at USD 7.53 on October 20, 2026 at 1:56 p.m. ET, while the year-low and year-high levels were USD 5.46 and USD 16.19. Analyst targets remain a counterweight. Investing.com reported that Mizuho initiated coverage on October 5, 2026 with an Outperform rating and a USD 22.00 price target. That target lies 192.16 percent above the USD 7.53 Nasdaq price. The rating also identified RGX-202 and ABBV-RGX-314 as key assets, while clinical and regulatory execution remain material factors. What dates shape the next step? wallstreetONLINE lists November 5, 2026 as the next quarterly update. The October 20 event therefore sits between the June 30 reporting period and the next scheduled corporate date. Market value and trading context. REGENXBIO's market capitalization was USD 497.1 million as of October 20, 2026, with a negative price-to-earnings ratio of 1.99. Its gene therapy pipeline covers retinal, neuromuscular and neurodegenerative diseases, according to the company profile. REGENXBIO stock was trading at EUR 6.70 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST, 8.87 percent above the Tradegate close of October 16, 2026 at EUR 6.15. The further course of trading is shown by the continuously updated real-time quote of REGENXBIO stock. REGENXBIO stock facts. * Company: REGENXBIO Inc. * ISIN: US75901B1070 * Ticker: RGNX * Primary exchange: Nasdaq * Price Lang & Schwarz (as of October 20, 2026, 7:49 p.m. CEST): EUR 6.70 * Change versus Tradegate close: plus 8.87 percent * Tradegate close (October 16, 2026): EUR 6.15 * Market capitalization: USD 497.1 million (as of October 20, 2026) * 52-week range: USD 5.46-16.19 (as of October 20, 2026) * Sector / Industry: Biotechnology * Next earnings date: November 5, 2026 Sponsored Ad Regenxbio stock: new analysis - 22 October. Fresh Regenxbio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US75901B1070 | RGNX | boerse | 70377039 | bgmi